现阶段治疗干性年龄相关性黄斑变性临床试验的总结与分析

Summary and analysis of clinical trials for the treatment of dry age-related macular degeneration

摘要:

年龄相关性黄斑变性(ARMD)是老年人不可逆性盲的主要原因之一。抗血管内皮生长因子(VEGF)药物已经成为新生血管性ARMD的一线治疗方法，极大地改变了其预后，但干性ARMD还是缺乏有效的治疗手段，以预防为主，目前几种临床治疗方法正在探索中，包括抗氧化治疗、补体治疗、神经保护治疗、基因治疗等。文章主要是对现有的治疗干性ARMD的临床试验及其进展进行归纳，以提供治疗干性ARMD的未来前景。一些临床试验已经得出了治疗干性ARMD有希望的结论，相信在不久的将来，会有越来越多的临床试验取得成功，为干性ARMD患者提供更有效的治疗方法。

Abstract:

Age-related macular degeneration(ARMD)is one of the leading causes of irreversible blindness in the elderly. Anti-vascular endothelial growth factor(VEGF)drugs have become the first-line treatment for neovascular ARMD, which has greatly changed the prognosis. However, dry ARMD still lacks effective treatment means, focusing on prevention. At present, several clinical treatment methods are being explored, including antioxidant therapy, complement therapy, neuroprotective therapy, gene therapy, etc. This review mainly summarizes the existing clinical trials and their progress on the treatment of dry ARMD, in order to provide future prospects for the treatment of dry ARMD. A number of clinical trials have already produced promising results for the treatment of dry ARMD, and it is believed that more and more clinical trials will be successful in the near future to provide more effective treatments for patients with dry ARMD.